MedTrace Logo

Predicting Neuromuscular Recovery in Surgical Patients Using Machine Learning

NCT05471882 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 240000

Last updated 2026-05-07

No results posted yet for this study

Summary

Despite emerging efforts to decrease residual paralysis and postoperative complications with the use of quantitative neuromuscular monitoring and reversal agents their incidences remain high. In an optimal setting, neuromuscular blocking agents are dosed in a way that there is no residual block at the end of surgery. The effect of neuromuscular blocking agents, however, is highly variable and is not only influenced by their dose, but also by several patient-related factors such as muscle status, metabolic activity, and anesthesia management. Accordingly, the duration of action is difficult to predict.

The PINES project will use artificial intelligence methods to develop a model that can accurately predict the course of action of neuromuscular blocking agents. It will be used to predict time to complete neuromuscular recovery (train-of-four \[TOF\] ratio \>0.9) and may provide as a decision support in the individual management of timing and dosing of neuromuscular blocking drugs and their reversal agents.

In a secondary analysis, the association between the choice of neuromuscular blocking agent and postoperative pulmonary complications will be evaluated.

Conditions

  • Residual Paralysis, Post Anesthesia
  • Postoperative Complications
  • Neuromuscular Blockade
  • Quantitative Neuromuscular Monitoring

Sponsors & Collaborators

  • Technical University of Munich

    collaborator OTHER

  • University Hospital Ulm

    lead OTHER

Principal Investigators

  • Manfred Blobner, MD PhD · Department of Anesthesiology and Intensive Care Medicine, University of Ulm,Ulm, Germany

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2026-09-01
Completion
2027-01-01

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05471882 on ClinicalTrials.gov